BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Eguchi Y, Mizuta T, Yasutake T, Hisatomi A, Iwakiri R, Ozaki I, Fujimoto K. High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. World J Gastroenterol 2006; 12(4): 556-560 [PMID: 16489668 DOI: 10.3748/wjg.v12.i4.556]
URL: https://www.wjgnet.com/1007-9327/full/v12/i4/556.htm
Number Citing Articles
1
Takumi Kawaguchi, Yumiko Nagao, Michio Sata. Independent factors associated with altered plasma active ghrelin levels in HCV‐infected patientsLiver International 2013; 33(10): 1510 doi: 10.1111/liv.12235
2
Joanna Olszok, Anna Wyganowska, Joanna Tarabura-Dragon, Franciszek Mazur, Mariusz Nowak. Selected adipocytokines and their potential role in the control of the course of chronic hepatitis B and CAnnales Academiae Medicae Silesiensis 2015; 69: 1 doi: 10.18794/aams/23858
3
Udayakumar Navaneethan, Nyingi Kemmer, Guy W. Neff. Review: Predicting the probable outcome of treatment in HCV patientsTherapeutic Advances in Gastroenterology 2009; 2(5): 287 doi: 10.1177/1756283X09339079
4
Toshihiko Mizuta. Can exercise be a new approach for chronic hepatitis C?Hepatology Research 2011; 41(10): 925 doi: 10.1111/j.1872-034X.2011.00885.x
5
Toshihiko Mizuta, Yasunori Kawaguchi, Yuichiro Eguchi, Hirokazu Takahashi, Keisuke Ario, Takumi Akiyama, Noriko Oza, Taiga Otsuka, Takuya Kuwashiro, Toru Yoshimura, Akitaka Hisatomi, Iwata Ozaki. Whole-Body Insulin Sensitivity Index Is a Highly Specific Predictive Marker for Virological Response to Peginterferon Plus Ribavirin Therapy in Chronic Hepatitis C Patients with Genotype 1b and High Viral LoadDigestive Diseases and Sciences 2010; 55(1): 183 doi: 10.1007/s10620-008-0691-2
6
Ching-Sheng Hsu, Jia-Horng Kao. Insulin resistance, adipocytokines, and hepatitis C virus infection: A missing link?Hepatology 2008; 47(2): 760 doi: 10.1002/hep.22066
7
Ming-Ling Chang, Zinger Yang, Sien-Sing Yang. Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease ProgressionInternational Journal of Molecular Sciences 2020; 21(21): 8308 doi: 10.3390/ijms21218308
8
Ming-Ling Chang, Chia-Jung Kuo, Hsin-Chih Huang, Yin-Yi Chu, Cheng-Tang Chiu, Salvatore Petta. Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and ImmunityPLOS ONE 2016; 11(11): e0166712 doi: 10.1371/journal.pone.0166712
9
Abdel-Rahman El-Zayadi. Hepatic steatosis: A benign disease or a silent killerWorld Journal of Gastroenterology 2008; 14(26): 4120-4126 doi: 10.3748/wjg.14.4120
10
Nyingi Kemmer, Guy W. Neff. Managing chronic hepatitis C in the difficult‐to‐treat patientLiver International 2007; 27(10): 1297 doi: 10.1111/j.1478-3231.2007.01613.x
11
Spilios Manolakopoulos, Sotirios Bethanis, Charis Liapi, Fotini Stripeli, Pantelis Sklavos, Alexandra Margeli, Aggeliki Christidou, Aggeliki Katsanika, Evangellos Vogiatzakis, Dimitrios Tzourmakliotis, Stamatios Theocharis. An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective studyBMC Gastroenterology 2007; 7(1) doi: 10.1186/1471-230X-7-17
12
N. V. Dhurandhar, D. Bailey, D. Thomas. Interaction of obesity and infectionsObesity Reviews 2015; 16(12): 1017 doi: 10.1111/obr.12320
13
F. Negro, S. Clément. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis CJournal of Viral Hepatitis 2009; 16(10): 681 doi: 10.1111/j.1365-2893.2009.01186.x
14
M Arai. The Effect on Gastric Emptying of Telaprevir-Based Triple Therapy for Chronic Hepatitis C PatientsArchives of Clinical Gastroenterology 2015; : 009 doi: 10.17352/2455-2283.000003
15
J. J. BLONSKY, S. A. HARRISON. Review article: nonalcoholic fatty liver disease and hepatitis C virus – partners in crimeAlimentary Pharmacology & Therapeutics 2008; 27(10): 855 doi: 10.1111/j.1365-2036.2008.03672.x